Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Pr
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people. The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 11 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use. More than 11,000 CNSide® tests have been performed at o...
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay.
This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.
The superior clinical utility of CNSide® over standard of care has been shown in 11 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.